Progyny, Inc. (PGNY) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Progyny, Inc. is a benefits management company specializing in fertility, family building, and women's health solutions. The company operates in a single segment and serves over 600 enterprise clients with approximately 7.2 million covered lives. The reporting period reflects continued growth in client base and utilization, alongside significant capital return activities.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Revenue | $350.5 million | $679.0 million |
| Net Income | $28.1 million | $52.3 million |
| Diluted EPS | $0.34 | $0.63 |
| Gross Margin | 25.5% | 25.4% |
| Operating Income | $40.0 million | $75.4 million |
| Adjusted EBITDA | $62.1 million | $118.7 million |
| Cash from Operations | N/A | $96.4 million |
| Cash & Equivalents | $152.6 million (as of June 30, 2026) | N/A |
| Marketable Securities | $84.3 million (as of June 30, 2026) | N/A |
Debt & Liquidity: The company maintains a $200 million revolving credit facility with no amounts drawn as of June 30, 2026. Total liabilities were $262.6 million, primarily consisting of current liabilities related to accounts payable and accrued expenses.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5% year-over-year (YoY) for the quarter and 3% YoY for the six-month period. This growth was driven by an increase in the number of clients and covered lives, partially offset by the non-renewal of a large client in 2025 (which had an extended transition period in the prior year).
- Profitability Expansion: Net income surged 64% YoY for the quarter ($28.1M vs. $17.1M) and 62% YoY for the six months ($52.3M vs. $32.2M). Gross margin expanded 180 basis points to 25.5% for the quarter.
- Expense Reduction: Operating expenses decreased significantly. General and Administrative (G&A) expenses dropped 14% YoY for the quarter, primarily due to a $5.9 million reduction in stock-based compensation (SBC) as a 2021 retention grant fully vested in late 2025. Sales and Marketing expenses decreased 2% YoY.
- Share Repurchases: The company aggressively returned capital to shareholders, repurchasing 6.7 million shares for $148.1 million during the first six months of 2026. The November 2025 program was completed, and the May 2026 program has $168.5 million remaining.
Guidance, Outlook, and Risks
Guidance: On August 6, 2026, management issued guidance for the third quarter and full year 2026. Specific numerical targets are not detailed in this filing text but are subject to standard forward-looking statement disclaimers.
Outlook: Management expects to continue investing in sales and marketing to drive new client acquisition and expand utilization within the existing base. The company anticipates that gross margins will be affected by geographic mix, pricing negotiations, and staffing levels.
Risks & Contingencies:
- Regulatory Environment: The company faces evolving regulations regarding reproductive rights, PBM operations (including the Consolidated Appropriations Act of 2026), and data privacy (HIPAA, CCPA).
- Client Concentration: While no single client exceeded 10% of revenue in the first half of 2026, the company notes that its largest clients account for a significant portion of revenue, and a significant number of clients are in the technology sector.
- Utilization Volatility: Revenue is heavily dependent on member utilization rates, which can fluctuate based on economic conditions and member demographics.
- Third-Party Dependencies: Operations rely on a network of fertility specialists and specialty pharmacies; disruptions or contract terminations could materially impact service delivery.
Investor Verification Checklist
- Stock-Based Compensation Trend: Verify the sustainability of the reduced SBC expense in 2026 compared to 2025, as the prior year included a large one-time vesting event.
- Client Renewal Rates: Confirm retention rates for large enterprise clients, particularly in the technology sector, given the noted sensitivity to industry headcount changes.
- Utilization Rates: Monitor the "Utilization - All Members" metric (0.56% for Q2 2026) to ensure it remains stable or grows as the client base expands.
- Regulatory Impact on PBM: Assess the financial impact of the new PBM reforms signed into law in February 2026 regarding rebate pass-throughs and disclosure requirements.
- Cash Flow Timing: Review the timing of accounts receivable collections versus provider payments, as working capital fluctuations are noted to be seasonal.